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ABSTRACT
Nuclear BMP2 and the Immune Response
Daniel S. Olsen
Department of Microbiology and Molecular Biology, BYU
Master of Science
Nuclear bone morphogenetic protein 2 (nBMP2) is a nuclear variant of the secreted
growth factor BMP2. Experiments in nBmp2NLStm mutant mice, which lack nBMP2 in the
nucleus, have shown that nBMP2 affects intracellular calcium transport in skeletal muscle and
hippocampal neurons. The objective of this study was to determine whether nBMP2 affects the
immune system, since activation of lymphocytes and other immune cells depends on intracellular
calcium transport. We found that spleens in nBmp2NLStm mutant mice were 24% smaller than
in wild type mice. The white pulp of the spleen contains many immune cells, particularly B and
T lymphocytes and reduced spleen size in the nBmp2NLStm mutant mice could be caused by a
reduced number of lymphocytes migrating to the spleen.
When mutants and wild types were challenged with an intravenous infection of 107 CFU
of S. aureus, they showed similar immune responses. Samples of blood, liver, spleen, kidney and
lymph nodes cultured three days after infection showed no difference in post infection bacterial
load between mutant and wild type. Likewise, post-infection weight loss and percent survival
were similar between mutant and wild type, suggesting that the innate immune response is
functional in nBmp2NLStm mice. However, when mice were challenged with a secondary
infection, immune response and spleen function were severely impaired. Mutant mice showed
higher levels of bacteria remaining in the blood and had lower rate of survival to day 3 after
secondary infection. In addition, CD4+ and CD8+ T-cell levels within mutant lymph nodes were
significantly reduced, indicating that nBMP2 is involved in the secondary immune response.

Keywords: BMP2, calcium transport, immunology, infection, lymphocytes, nuclear localization,
spleen function, T-cells
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INTRODUCTION

Nuclear bone morphogenetic protein 2 (nBMP2) is a recently discovered nuclear variant
of the secreted growth factor bone morphogenetic protein 2 (BMP2) [1]. nBMP2 is synthesized
from the same gene and same mRNA transcript as the secreted BMP2. Because of this, it is
possible that some of the functions that have been attributed to BMP2 are actually carried out by
nBMP2. There is, therefore, a great need to characterize the specific functions of nBMP2 in
order to differentiate them from those of the secreted BMP2.
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor β
(TGF-β) superfamily of growth factors. The TFG-β superfamily has many subfamilies, including
BMPs and growth differentiation factors [2]. Over twenty BMP family members have been
identified and characterized, making BMPs the largest subfamily of the TGF-β superfamily.
BMPs are involved in many different developmental pathways, including axis formation, limb
patterning, heart development, neural crest cell migration, neurogenesis, and apoptosis [3].
BMP2 plays an important role in the development of bone, cartilage and heart, as well as
directing the development of neural crest cells [4, 5].
BMP2, like other members of the TGF-β superfamily, is first produced as a
preproprotein, including an N-terminus signal peptide which directs it to the endoplasmic
reticulum (ER) for processing as part of the secretory pathway. During this process, the
proprotein is cleaved by proprotein convertases, releasing the C-terminal peptide. The C-terminal
peptide homodimerizes to form the mature secreted growth factor. nBMP2 is produced by
alternative translation of the BMP2 mRNA transcript. Alternative translation begins at a
downstream start codon, bypassing the signal peptide and thereby avoiding the processing and
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cleavage involved with the secreted BMP2. As a result, a nuclear localization signal (NLS) found
within the site of cleavage is left intact, directing nBMP2 to be translocated from the cytoplasm
to the nucleus.
A line of viable mice bearing a targeted inactivation of nBmp2 (nBmp2NLStm) has been
successfully created. This line was created by targeted mutagenesis of the NLS, thereby
preventing BMP2 from translocating to the nucleus even when translation begins from the
alternative start site. While Bmp2 null mice are nonviable, displaying fatal defects in
amnion/chorion and cardiac development [5], nBmp2NLStm mice are viable and fertile.
Extensive examination of nBmp2NLStm mice has shown no difference in cartilage and bone
formation compared to wild type mice, indicating that function of the secreted BMP2 has not
been altered. Although nBmp2NLStm mice are viable and fertile, they do display abnormal
phenotypes compared to wild type mice, including impaired learning and memory along with
abnormal muscle contraction and relaxation [6, 7].
In studies testing memory and learning, mutant mice showed greater difficulty in
adapting acquired memory to environmental changes, and reduced recognition of novel objects.
They also showed reduced long-term potentiation, one of the primary cellular mechanisms
mediating learning and memory. These phenotypes are similar to those of ryanodine receptor
type 3 (RyR3) knockout mice [8]. In addition to these altered cognitive phenotypes, mutant mice
also showed decreased skeletal muscle relaxation rates and decreased sarco/endoplasmic
reticulum Ca2+ ATPase (SERCA) activity. Both RyR3 and SERCA are calcium transporters
heavily involved in regulating intracellular calcium levels. These results indicate that lack of
nuclear localized BMP2 leads to dysregulation of intracellular calcium transport.
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In addition to its involvement in cognitive function and muscle contraction, intracellular
calcium transport is also a key component in the activation and differentiation signaling
pathways of many immune cells, including T-cells, B-cells, dendritic cells and macrophages [911]. In general, the activation of immunoreceptors on the cell surface triggers a series of protein
tyrosine kinase cascades that result in increases in intracellular concentration of Ca2+. This is
largely mediated by activation of inositol-1,4,5-trisphosphate (IP3), which then binds to its
receptor (IP3R) in the endoplasmic reticulum (ER) membrane, causing a rapid release of Ca2+
from ER stores into the cytosol [10, 12]. There are also various calcium channels in the cell
membrane, referred to as store-operated calcium channels (SOCC), which are activated by
depletion of ER calcium stores. Calcium stores in the ER are replenished primarily through
SERCA, which has been shown to have decreased activity in muscle of nBmp2NLStm mutant
mice. It is therefore possible that lack of nBMP2 could have a similar effect on the intracellular
calcium transport function of lymphocytes and other immune cells. This would result in a
reduced ability of nBmp2NLStm mutant mice to mount an appropriate immune response.
The purpose of this work was to determine the effect of nBMP2 on the immune response
to a systemic bacterial infection. Lack of nBMP2 is shown to result in impaired spleen function
as well as reduced T-cell levels within lymph nodes, leading to a disrupted immune response to
secondary infection.

3

MATERIALS AND METHODS

MOUSE INFECTION STUDIES
Overview
In order to determine whether nBMP2 plays a role in the immune response to bacterial
infection, nBmp2NLStm +/+ (wild type) and nBmp2NLStm -/- (mutant) mice were infected with S.
aureus by intravenous injection through the tail vein. Mice were divided into groups to be
analyzed at various points in infection. Uninfected controls were injected with 200 µL of sterile
PBS and examined 3 days later. Figure 1 shows the experimental setup for primary and
secondary infections.
With each group of mice infected, the inoculum concentration was kept constant and the
injection volume was varied from 150 – 250 μL, depending on individual mouse weight, to
ensure that each mouse received the proper dose. For primary infections, a dose of 3×105 CFU/g
was administered for mice that were to be analyzed 3 days after infection and a dose of
1×104 CFU/g was given to mice that were to be analyzed at 8 days after infection. For secondary
infections, a dose of 1×104 CFU/g was administered and followed by a secondary injection,
35 days later, of 3×105 CFU/g. Inoculum concentration was verified on each day of injections by
standard plate count.
Mice were monitored for up to eight days after primary infections and three days after
secondary infection. A pain and distress score for the categories of weight loss, appearance,
clinical signs and unprovoked behavior was assigned each day of monitoring. Samples were
obtained on the day indicated for each group and response to the infection was measured by postinfection bacterial load, lymphocyte distribution, histology and hematology.
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Mouse Colony Maintenance
Heterozygous nBmp2NLStm mice were bred in the Brigham Young University specific
pathogen free (SPF) animal facility. After weaning, mice were genotyped and transferred to the
non-SPF animal care facility where they were housed and maintained throughout the duration of
the study. All mice were given a standard chow and water diet ad libitum and kept in a
temperature-controlled (21-22°C) room with a 12:12 hour light:dark cycle. Experiments were
performed with mice between the ages of 6-8 months. All experiments were performed in
accordance with approved Institutional Animal Care and Use Committee (IACUC) protocol.

Bacterial Culture Maintenance
S. aureus, ATCC strain 12600, was obtained from the Microbiology and Molecular
Biology department stockroom as a broth culture in tryptic soy broth. Organism identification
was verified through morphology, Gram stain, catalase test, and mannitol fermentation.
Subsequent passages were created by alternating between a standard streak plate and a broth
culture. Streak plates were performed on Mannitol Salt Agar (Alpha Biosciences) and broth
cultures were prepared in LB Broth (BD Biosciences). All cultures were incubated for 24 hours
at 37°C and stored at 4°C. Broth cultures were placed on a rotating platform at 120 rpm during
incubation. Culture titer was determined regularly by standard plate count.

Tail Vein Injections
Prior to performing injections, mice were warmed in an empty cage on a heat pad to
dilate the tail vein. The S. aureus culture was diluted to desired concentration in phosphate
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buffered saline (PBS). Mice were placed in a restrainer and injection solution, either bacterial
culture or sterile PBS, was injected using a 1 mL syringe and a 27 gauge needle. Injection dose
was verified following injection by standard plate count.

Tissue Preparation
Mice were euthanized by CO2 inhalation followed by cervical dislocation. Blood samples
were taken by cardiac puncture and placed in PBS containing ethylenediaminetetraacetic acid
(EDTA) at a final concentration of 1.8 mg/mL to prevent clotting. Mice were then dissected to
obtain liver, kidney, spleen and inguinal lymph node samples. Solid tissue samples were
weighed, placed in PBS (5-10 mL for liver, spleen and kidney samples; 3-5 mL for lymph node
samples) and homogenized using a dounce homogenizer.

Post-Infection Bacterial Load
Tissue samples were serially diluted in ten-fold increments (0.5 mL into 4.5 mL) using
PBS as needed to get colony counts within countable range. 100 µL aliquots were plated in
triplicate on MSA to select for growth of S. aureus. Plates were incubated for 24-48 hours at
37°C. Bacterial load was calculated as CFU/mL for blood samples and CFU/g for solid tissue
samples.

Flow Cytometry
Mice were dissected to obtain spleen, thymus and lymph node (inguinal, mesenteric, and
lumbar) samples. Tissues were ground using frosted microscope slides and filtered through
70 μm nylon mesh (BD Biosciences) to prepare single cell suspension in PBS. Cells were
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centrifuged and resuspended in 5 mL of red blood cell lysis buffer (388 mM NH4Cl, 29.7 mM
NaHCO3, 25 μM Na2EDTA) for 5 minutes. After red blood cell lysis, samples were centrifuged
and resuspended in 500 μL of PBS. In order to reduce non-specific binding of the antibodies, an
FC receptor block was performed by adding anti-mouse CD16/32 antibody to cells (1 μL Ab per
100 μL of cells) and incubating at room temperature for 15 minutes. Samples were centrifuged
and resuspended in antibody staining solution (1 μL antibody in 200 μL PBS) for 30 minutes.
Refer to Table 1 for antibody grouping. All antibodies used were from eBiosciences. Following
staining, samples were rinsed once with PBS and measured on a FACSCanto Flow Cytometer
(BD Biosciences). Results were analyzed using Summit Software v4.3 (Beckman Coulter) and
FlowJo v10.0.6 (Tree Star).

Histology
Spleen samples were fixed overnight in 4% paraformaldehyde in PBS at 4°C. After
paraformaldehyde fixation, samples were dehydrated using increasing concentrations of ethanol
and processed in a Citadel 1000 tissue processor. Refer to Table 2 for details of the processing
cycle. Samples were then embedded in paraffin wax and 5-7 μm sections were prepared.
Sections were stained using hematoxylin and eosin (H&E) (Table 3) and observed on a Zeiss
Imager A.1 brightfield microscope.

Hematology
To determine red blood cell count, 10 μL of blood was added to 990 μL 1.5 mg/mL
EDTA in PBS. Additional dilutions were performed as needed in PBS to get cells in countable
range. Cells were counted on a hemocytometer.
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To determine white blood cell count, 10 μL of blood was added to 190 μL RBC Lysis
Buffer (388 mM NH4Cl, 29.7 mM NaHCO3, 25 μM Na2EDTA). Sample was mixed and allowed
to sit for 5 minutes. Cells were counted on a hemocytometer.

IDENTIFICATION OF NBMP2 BINDING PARTNERS
Overview
In order to identify potential binding partners of nBMP2 and better understand the role it
plays inside the nucleus, co-immunoprecipitation (Co-IP) and mass spectrometry experiments
were performed. Using site-directed mutagenesis, versions of nBmp2 containing FLAG, Myc
and HA tags were created. Human embryonic kidney 293 (HEK-293) cells were transfected with
the tagged versions of nBmp2, followed by co-immunoprecipitation and mass spectrometry
analysis.

Site-Directed Mutagenesis
Tagged versions of nBmp2 were prepared by site directed mutagenesis using a
QuikChange® II Site-Directed Mutagenesis Kit (Stratagene) to alter the rat nBmp2 gene
contained on a pcDNA3.1 plasmid. FLAG, Myc and HA tag sequences were inserted either
upstream or downstream of the gene so that they were present at either the N- or C-terminus of
the expressed protein. A linker sequence of five glycine residues was inserted between the tag
and the gene sequence to reduce allosteric interference and improper protein folding that are
possible when adding a tag sequence to a protein. The primers used for each of the tagged
versions are shown in Table 4.

8

After mutagenesis was complete, plasmids were purified from the mutagenesis samples
using a GenElute™ Plasmid Miniprep Kit (Sigma). Samples were then sequenced in the Brigham
Young University DNA Sequencing Center to verify proper insertion and orientation of tags.
Plasmids containing properly inserted tags were transformed into E. coli cells and purified using
a Plasmid Midi Kit (QIAGEN).

Cell Culture
HEK293 cells were grown in Dulbecco’s Modification of Eagle’s Medium / Ham’s F12
50/50 Mix (Corning cellgro), supplemented with 10% fetal bovine serum and 1% L-Glutamine
(Hereafter referred to as DMEM/F12). Cells were grown in 75 cm2 tissue culture flasks
(Sarstedt) and were regularly passaged every 3-4 days. All incubation was performed at 37°C
and 5% CO2.

Immunofluorescent Staining of Cultured Cells
To verify endogenous expression of nBmp2 in HEK293 cells, immunofluorescent
staining was performed. HEK293 cells were seeded (5×104 cells in 0.5 mL DMEM/F12 per
chamber) in Lab-Tek®II Chamber Slides™ (Thermo Fisher). Cells were incubated for 2 days and
washed with 400 μL of PBS. After washing, cells were fixed by adding 200 μL 4%
paraformaldehyde/PBS to each well for 30 minutes on a rotating platform. The
paraformaldehyde solution was then removed and the chambers were detached from the slide,
followed by two 5 minute rinses and a 20 minute rinse in PBS.
Cells were incubated in 300 μL of permeabilization/blocking solution (1% bovine serum
albumin,

0.3%

Triton-X

100

in

PBS)

at
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room

temperature

for

40

minutes.

Permeabilization/blocking solution was removed from the slide and incubated with primary
antibody (BMP-2 rabbit polyclonal IgG, Santa Cruz Biotechnology) at a 1:50 dilution in
antibody staining solution (0.1% bovine serum albumin, 0.3% Triton-X 100 in PBS) for 2 hours
at room temperature and then overnight at 4°C.
Following primary antibody stain, cells were rinsed for 3 times for 5 minutes each in
PBS. Cells were then incubated with secondary antibody (Alexa Fluor® 488 goat-anti-rabbit IgG
(H+L), Invitrogen) at 1.8 μg per 300 μL of antibody staining solution for 30 min. at room
temperature. Following secondary antibody stain, cells were rinsed 3 times for 5 minutes in PBS.
Cells were then counterstained using TO-PRO-3-Iodide (Invitrogen) at 1:1000 dilution in PBS
for 10 minutes and again rinsed 3 times for 5 minutes in PBS.
Coverslips were mounted on the slides using Fluoromount-G™ mounting medium
(SouthernBiotech). Slides were observed on an Olympus FluoView FV1000 confocal laser
scanning microscope.

Transfection
HEK293 cells were grown to 85-95% confluency and seeded in a 6-well tissue culture
plate (3×105 cells per well in 2 mL DMEM/F12). Cells were incubated for 2 days at 37°C and
5% CO2. Transfection was performed as follows, using Lipofectamine® 2000 (Invitrogen).
For each well of cells, 10 μL of Lipofectamine® 2000 was added to 250 μL of OptiMEM® I Reduced Serum Media (Gibco), mixed gently and incubated at room temperature for
5 minutes. 4 μg of DNA was added to 250 μL of Opti-MEM and mixture was added to the
Lipofectamine® 2000 transfection mixture and mixed gently. Solution was allowed to incubate at
room temperature for 20 minutes, after which it was added drop-wise to the well of cells and the
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plate was gently rocked to allow mixing. Transfected cells were incubated at 37°C and 5% CO2
for 2 days before further use to allow for expression of transfected DNA.

Co-Immunoprecipitation
Transfected HEK293 cells were lysed using NP-40 lysis buffer (50 mM Tris-HCl,
150 mM NaCl, 0.5 % NP-40, 50 mM NaF) on ice for 30 minutes. Immediately prior to use, the
following were added to the lysis buffer to be at the listed final concentration: 1 mM Na3VO4,
1 mM DTT, 1x protease inhibitors (Halt™ Protease Inhibitor Cocktail, Thermo Scientific), 1 mM
PMSF. Cells were collected into a microcentrifuge tube and rotated at 4°C for 10 minutes to
further lyse cells. After lysis, samples were centrifuged at 14,000 rpm (16,000 rcf) for 5 minutes
and supernatant was collected into a new, pre-chilled microcentrifuge tube.
Immunoprecipitation was performed on the lysate samples using either primary
antibodies against the tag and Protein A/G PLUS-Agarose beads (Santa Cruz Biotech), or antiMyc mouse mAb conjugated to sepharose beads (Cell Signaling). For the A/G bead method,
lysate was incubated with primary antibody at 1:250 dilution overnight at 4°C. After primary
antibody incubation, Protein A/G beads were added for 1 hour at 4°C (5 μL beads per 1 μL
primary antibody used). For the sepharose bead method, antibody-conjugated beads were added
to cell lysate (20 μL per 500 μL of lysate) and incubated overnight at 4°C.
Following immunoprecipitation, samples were centrifuged at 2000 rpm (326 rcf) for
3 minutes and washed 3 times with cold lysis buffer (500 μL per wash). Samples were then
placed in boiling water for 5 minutes and centrifuged for 1 minute to remove protein from beads.
Supernatant was saved and stored at 4°C.
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RESULTS

MOUSE INFECTION STUDIES

Uninfected Controls
Uninfected wild type and mutant mice were examined to determine if there were any
significant innate differences between them without being challenged with bacterial infection.
Tissue weights were examined for kidney, liver and spleen. No difference was observed in either
kidney or liver size, however mutant spleens were found to be an average of 24% smaller than
wild type (p=0.003, Table 5, Figure 2).
Because a significant difference between wild type and mutant spleen size was observed
in uninfected controls, it was important to determine whether there was some innate structural or
functional difference between wild type and mutant spleens. To look at tissue structure,
uninfected spleens were sectioned and stained with H&E stain. The spleen has two main
structural compartments, red pulp and white pulp, which correspond to its main functions. The
red pulp acts as a blood filter to remove pathogens and aging or damaged erythrocytes. As a
secondary lymphoid tissue, the spleen also houses many lymphocytes within the white pulp. No
obvious differences between wild type and mutant spleens were observed in the H&E stained
tissue samples (Figure 3).
In order to test blood filtering function of the spleens, blood cell counts were performed.
It would be expected that if the filtering capacity of the mutant spleens was diminished due to
their smaller size, then the mutant mice would have higher counts of red blood cells. However,
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neither red blood cell, nor white blood cell counts showed any significant difference between
uninfected wild type and mutant mice (Figure 4).
As the white pulp is a major site of lymphocyte storage, it was possible that the smaller
spleen size observed in the mutant mice was due to fewer lymphocytes being present. To
investigate this, the lymphocyte distribution of cells within the spleen was identified using flow
cytometry. Common cell markers for many immune cell types were measured (Table 1). There
were no differences in the percentage of each cell type present in the wild type and mutant
spleens (Figure 5).
Taken together, these results indicate that although the spleens of mutant mice are
significantly smaller than wild type prior to any treatment, they appear to still be functional and
composed of the same cell types in equal proportions. There were no other significant
differences observed between wild type and mutant mice.

Primary Infection
To determine the effect of nBMP2 on the immune response to bacterial infection,
nBmp2NLStm and wild type mice were challenged with a systemic infection of S. aureus. An
infection dose of 3×105 CFU/g was administered intravenously. On the third day after infection,
blood, kidney, liver, lymph node and spleen samples showed no difference between wild type
and mutant mice in remaining bacterial load (Figure 6). The response to the infection as
indicated by percent weight loss (Figure 7) and the percent of mice that survived to day 3 was
also the same between wild type and mutants.
Tissue weight was compared for the kidney, liver and spleen samples. While the kidney
and liver showed no difference in weight between wild type and mutants, spleens from the
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mutant mice were significantly smaller than those from wild type mice (Figure 8). All three
tissues had increased in size compared to uninfected controls, however, spleen size increased
more than the other two tissue types (Table 5). This is not unexpected, as splenic inflammation is
typical in response to infection [13].
Overall, at day 3 after infection, the mutant mice responded to the treatment similarly to
wild type, indicating that the primary innate immune response is unaffected by the lack of
nuclear BMP2. In order to test the function of the adaptive immune response, which typically
takes from 5-7 days to respond, mice were infected and samples were tested 8 days after
infection. Since the infection dose of 3×105 CFU/g used for the 3 day infections was a fatal dose
for approximately 25% of the mice by day 3 (Figure 13a), the dose was lowered to 1×104 CFU/g
for subsequent experiments.
Both wild type and mutant mice displayed a similar response to the infection as shown by
percent weight loss (Figure 9). Both groups appear to begin recovering from the infection around
day 5. Post infection bacterial load at day 8 showed no differences between wild type and mutant
mice for blood, liver, spleen, kidney and lymph node samples (Figure 10). In both wild type and
mutants, bacteria were completely cleared from the blood and only trace amounts remained in
liver and spleen. Kidney and lymph nodes samples both had approximately the same amount of
bacteria as at day 3.
Wild type and mutant tissue weights were also the same for spleen and kidney samples.
Mutant livers were 21% smaller than wild type at day 8 (Table 5). While this difference is
statistically significant, there were no differences in liver size prior to infection or at any other
stage of infection. Further investigation into the cause of this difference was, therefore, not
pursued.
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As with the innate response, the adaptive response of the mutant mice to a primary
infection appears to function properly. In order to test the ability of the mice to fully recover
from the infection, mice were infected and allowed to recover for one month. Samples were
tested on day 35 after infection. Both wild type and mutant mice showed complete clearance of
bacteria from blood, liver, spleen, kidney and lymph nodes by day 35. In addition, there were no
differences in red or white blood cell count (Figure 11). While both wild type and mutant mice
tested at day 35 showed equal ability to fully clear the primary infection, mutant mice had a
slightly lower percent survival than wild type mice during the first 8 days of infection (Figure
12), indicating that their response may be slightly impaired. However, all other results show that
both wild type and mutant mice are able to fully recover from primary infection by day 35.

Secondary Infection
The function of the primary immune response is to clear the infection as quickly as
possible. On the other hand, the function of the secondary immune response, executed primarily
by B and T lymphocytes, is to prevent the host from succumbing to infection again.
Experimental results indicate that, although there are significant differences in some of the main
tissues involved, the primary response of mutant mice is fully functional. In order to test the
secondary response, mice were challenged with a secondary infection after being allowed to
recover from the primary infection. Mice received a lower dose, priming infection at
1×104 CFU/g and allowed to recover for 35 days. On day 35, a higher dose secondary infection
was administered at 3×105 CFU/g.
It was quickly apparent that the ability of the mutant mice to respond to the secondary
infection was severely impaired. While nearly all wild type mice survived to day 3 after
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secondary infection, only 64% of mutant mice did (Figure 13), even though the response of wild
type and mutant mice as shown by percent weight loss showed no difference (Figure 14). This
indicates that while wild type mice were effectively immunized by the priming dose prior to
secondary infection, mutant mice were not.
Tissue weights again showed no difference in the size of liver or kidney samples,
however mutant spleens were 35% smaller than wild type (p=0.001, Figure 15). In fact, while the
wild type spleens increased in size compared to day 3 after primary infection, mutant spleens
were similar in size at day 3 after secondary infection as they were at day 3 after primary
infection (Figure 16). This shows a reduced ability of mutant spleens to respond to secondary
infection.
With such a severely reduced spleen size, it would be expected that mutant mice would
be less efficient at filtering blood and indeed, there was a significant difference in post-infection
bacterial load of blood in mutant mice compared to wild type (Figure 17). Mutant mice had a
60 fold increase in the number of bacteria remaining in the blood 3 days after secondary
infection compared to wild type (Figure 18). In addition, mutants had lower levels of white blood
cells in the blood (Figure 19a). While this difference is not statistically significant, possibly due
to the low sample size available, it is suggestive that there could possibly be a difference in the
number of circulating lymphocytes. Values for both wild type and mutant samples are clustered
together with one outlying sample each, thereby reducing the average difference between them
(Figure 19b). A larger sample size would give a more accurate view.
Flow cytometry analysis of the spleen showed no difference between wild type and
mutant mice for any of the immune cells tested (Figure 20). However, histological analysis of
post-secondary infection spleens showed lower levels of hemosiderin laden macrophages in the
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mutants compared to wild type (Figure 21). It is a normal function for macrophages in the spleen
to engulf damaged erythrocytes or free hemoglobin in order to recycle and store the iron
contained therein. Hemosiderin is an iron storage complex produced by this process. While there
is no difference in macrophage abundance in wild type or mutant spleens, as indicated by the
flow cytometry data, the lack of hemosiderin laden macrophages within mutant spleens indicates
that macrophage phagocytic function is disrupted in the mutant mice.
Along with the differences observed in the spleen, the lymph nodes of wild type and
mutant mice also showed significantly different responses to secondary infection. Because
corresponding lymph node samples were not able to be obtained from every mouse examined, an
accurate quantitative comparison of wild type and mutant lymph node size was not able to be
performed. However, it was observed that lymph nodes in wild type mice following secondary
infection were consistently larger and easier to locate than in mutant mice. In particular, the
lumbar pair of lymph nodes was considerably smaller in mutant mice than wild type (Figure 22).
Flow cytometry analysis revealed that there were significantly lower levels of CD4+ and CD8+
T-cells in mutant lymph nodes compared to wild type (Figure 23). Mutant CD4+ T-cell levels
were 70% of wild type (p=0.033), and mutant CD8+ T-cell levels were 61% of wild type
(p=0.040).
In addition to the significantly lower levels of CD4+ and CD8+ T-cells observed in mutant
lymph nodes, two CD4+ T-cell subsets also showed differences in wild type and mutant levels.
CD4+/CD25+ regulatory T-cell levels were 68% higher in mutants (p=0.064) and CD4+/CD62L+
naïve helper T-cells were 45% lower in mutants (p=0.062). Also, mutants had much higher
levels of F4/80+ mature macrophages present in the lymph nodes than wild type (p=0.144).
While these differences are not quite statistically significant at the 0.05 level of significance, they
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suggest that there is also a possible difference the level of these CD4+ T-cell subsets and mature
macrophages present in mutant lymph nodes after secondary infection.
T-cells come from hematopoietic precursor cells formed in the bone marrow and mature
within the thymus. While there were lower levels of T-cells found within the lymph nodes of
mutant mice, there were no differences between mutant and wild type mice in CD4+ or CD8+
T-cell levels in the thymus (Figure 24). This indicates that T-cell development is functional in
mutant mice and the observed deficiencies in lymph node T-cells (Figure 25) are likely due to
disruption of function, such as migration signaling pathways, rather than development.

IDENTIFICATION OF NBMP2 BINDING PARTNERS
In order to better understand how nBMP2 functions within the cell, it is important to
identify the other proteins it interacts with. This was accomplished using Co-IP from transfected
HEK293 cells. In order to be confident that interactions observed were valid, it was necessary to
first verify that nBMP2 is expressed endogenously in HEK293 cells. Immunofluorescent staining
of non-transfected cells shows endogenous expression of nBMP2 (Figure 26).
Tagged versions of nBmp2 were prepared using site-directed mutagenesis. FLAG, Myc
and HA tags were inserted upstream and downstream of the gene so that they would be located at
the N- or C-terminus of the expressed protein. Of the six possible variations (N-FLAG, C-FLAG,
N-Myc, C-Myc, N-HA, C-HA), five were successfully created. After multiple attempts,
transformation of competent cells using N-HA was unsuccessful, so the other five versions were
used.
Transfection of HEK293 cells with C-Myc-nBMP2 resulted in successful expression of
tagged protein (Figure 27a). Following Co-IP with Myc-conjugated sepharose beads, the tagged

18

protein was still present in the sample, as expected. Using A/G beads for the Co-IP also yielded
purified nBmp2, however a lower amount was present, along with higher levels of non-specific
binding of the A/G beads (Figure 27b).
Due to unavailability of the mass spectrometry equipment, samples have not been able to
be analyzed at this point. This will be completed by future students.
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DISCUSSION

It has been shown herein that lack of nuclear BMP2 results in an impaired secondary
immune response to systemic S. aureus infection in mice. Mutant mice do not appear to be
innately immunocompromised, in that their response to primary infection is similar to that of
wild type mice. In contrast, mutant response to secondary infection is limited. Wild type mice
showed an increased rate of survival after secondary infection than after primary infection,
indicating that they were effectively immunized by primary exposure to the pathogen. Mutant
mice, on the other hand, showed no effect of immunization and actually had a decreased rate of
survival following secondary infection compared to primary infection. These results indicate
dysfunction of the secondary immune response in the mutant mice, particularly in memory cells
which provide the protective effect against repeated exposure to a pathogen.
Previous work with nBmp2NLStm mutant mice has shown that they have impaired
intracellular calcium transport, resulting in decreased muscle strength and cognitive disorders.
Intracellular calcium transport is a key component of immune cell activation and migration
signaling pathways [9-12, 14], particularly in B- and T-lymphocytes. Therefore, it is likely that
the observed immune response in the mutant mice is due, at least in part, to reduced B-and T-cell
function caused by disrupted intracellular calcium transport.
The reduced levels of T-cells within lymph nodes of nBmp2NLStm mutant mice
following secondary infection further support the hypothesis that lack of nBMP2 impairs
lymphocyte function. T-cells are generated in the bone marrow and mature in the thymus.
Following maturation, they are released into circulation throughout the body. In response to
infection, it is common for lymph nodes to enlarge due to accumulation and proliferation of T-

20

cells as they respond to activation signals from antigen presenting cells. Similar levels of T-cells
were observed in the thymus of both mutant and wild type mice, indicating that T-cell generation
is not affected in the mutants. Within the lymph nodes, however, significantly lower levels of
both CD4+ and CD8+ T-cells were present in mutant mice than in wild type mice. Therefore, it is
possible that, although T-cell generation is unaffected in mutant mice, the ability of those T-cells
to respond to activation and migratory signals has been disrupted.
In order to further determine the effect of nBMP2 on lymphocyte function, it will be
important to test antibody production in mutant mice. Proper antibody production by B-cells is a
key factor in secondary immune response. B-cells and T-cells are both direct descendants of
small lymphocyte precursor cells and are similar in many ways; including surface morphology
[15] and dependence on intracellular calcium transport for proper activation signaling [12, 16,
17]. I suspect that, in addition to inhibiting T-cell function, lack of nBMP2 also impairs B-cell
function. Furthermore, as CD4+ helper T-cells are a main source of antigen presentation to Bcells, leading to their activation and subsequent antibody production, a deficiency in T-cell
function could easily lead to decreased antibody production.
In addition to the T-cell phenotypes observed in mutant mice, macrophage function was
also inhibited. Following secondary infection, mutant spleens showed much lower levels of
hemosiderin laden macrophages. Hemosiderin is an iron storage complex produced when
macrophages engulf damaged erythrocytes or free hemoglobin in order to recycle and store the
iron contained therein [13]. While this process is typically the result of hemorrhage, it is possible
that it is the result of S. aureus infection. Iron is an essential nutrient for both S. aureus and the
hosts it infects. One mechanism of pathogenesis employed by S. aureus is the secretion of
hemolysins in order to rupture red blood cells and gain access to the iron stored within
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hemoglobin [18, 19]. This would give splenic macrophages the opportunity to engulf high levels
of free hemoglobin resulting from red blood cell lysis. The high level of hemosiderin laden
macrophages observed in wild type spleens, but not in mutants, provides evidence that lack of
nuclear BMP2 leads to decreased phagocytic function of macrophages.
Neutrophils, one of the most common white blood cell types and efficient phagocytes, are
closely related to macrophages as both are descendants of myeloblasts. Neutrophils are key
players in the immune response to S. aureus infection [20, 21]. Berger et al. [22] have shown
that intracellular calcium concentration regulation is necessary for increased complement
receptor expression involved in neutrophil activation. In addition, intracellular calcium transport
is a key element of neutrophil chemotaxis [23] and phagocytosis [24]. Although neutrophils are
primarily involved in innate immune function, which appears to be functional in nBmp2NLStm
mutant mice, Rakhmilevich [25] has shown that neutrophil function is necessary for resolution of
both primary and secondary infection with Listeria monocytogenes. It is, therefore, also possible
that neutrophil function has been disrupted in nBmp2NLStm mutant mice, leading to poor
response to secondary infection.
Along with impaired function of immune cells, lack of nBMP2 in mice also leads to
reduced spleen size relative to wild type mice. This difference was present prior to treatment and
throughout various stages of infection, however, it was most pronounced following secondary
infection. While wild type spleens continued to increase in size following secondary infection,
mutant spleens did not, indicating a disruption of splenic function. Teixeira et al. [26] have
shown that the spleen is necessary for proper recovery from S. aureus infection. Accordingly,
nBmp2NLStm mutant mice showed reduced spleen function, as well as a severely impaired
immune response to secondary infection with S. aureus.
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The importance of proper spleen function has been well established and the effects of
hyposplenism and asplenism on the immune response have been thoroughly studied [27-31].
Absence of the spleen or loss of splenic function leaves individuals at a much higher risk of rapid
onset of septicemia and overwhelming infection [32]. Much of the murine research related to
spleen function involves partial or complete splenectomy as a method of determining the effects
of the spleen on immune function. Currently, there is not a mouse model available for use in
studying the effect of reduced spleen size on immune response. The nBmp2NLStm mouse line
has potential to be used as such a model, thereby allowing research of spleen function without
the need for surgical procedures.
In order to more fully understand the involvement of nBMP2 in the immune response to
bacterial infection, it will be vital to determine which pathways it is involved in and the
molecular mechanisms thereof. Work is currently underway to identify binding partners of
nBMP2 using co-immunoprecipitation and mass spectrometry. This will provide important clues
for determining, on a molecular level, how nBMP2 affects the immune response.
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Table 1: Antibodies used for lymphocyte identification.
Marker

Group
1

Group
2

Group
3

Group
4

Group
5

Stain

Antibody

Clone

eBioscience
Reference Number

CD11b

FITC

Anti-Mouse CD11b FITC

M1/70

11-0112-82

CD8a

PE

Anti-Mouse CD8a PE

53-6.7

12-0081-82

®

CD4

APC

Anti-Mouse CD4 eFluor 660

GK1.5

50-0041-82

Gr-1

PE-Cy7

Anti-Mouse Ly-6g (Gr-1) PE-Cy7

RB6-8C5

25-5931-82

B220

FITC

Anti-Human/Mouse CD45R (B220) FITC

RA3-6B2

11-0452-82

CD8a

PE

Anti-Mouse CD8a PE

53-6.7

12-0081-82

®

CD4

APC

Anti-Mouse CD4 eFluor 660

GK1.5

50-0041-82

Gr-1

PE-Cy7

Anti-Mouse Ly-6g (Gr-1) PE-Cy7

RB6-8C5

25-5931-82

CD11c

FITC

Anti-Mouse CD11c FITC

N418

11-0114-82

CD5

PE

Anti-Mouse CD5 PE

53-7.3

12-0051-82

®

CD4

APC

Anti-Mouse CD4 eFluor 660

GK1.5

50-0041-82

Gr-1

PE-Cy7

Anti-Mouse Ly-6g (Gr-1) PE-Cy7

RB6-8C5

25-5931-82

F4/80

FITC

Anti-Mouse F4/80 FITC

BM8

11-4801-82

CD3e

PE

Anti-Mouse CD3e PE

145-2C11

12-0031-82

®

CD4

APC

Anti-Mouse CD4 eFluor 660

GK1.5

50-0041-82

Gr-1

PE-Cy7

Anti-Mouse Ly-6g (Gr-1) PE-Cy7

RB6-8C5

25-5931-82

CD4

FITC

Anti-Mouse CD4 FITC

GK1.5

11-0041-82

CD44

PE

Anti-Human/Mouse CD44 PE

IM7

12-0441-82

CD25

APC

Anti-Mouse CD25 APC

PC61.5

17-0251-82

Gr-1

PE-Cy7

Anti-Mouse Ly-6g (Gr-1) PE-Cy7

RB6-8C5

25-5931-82

MEL-14

47-0621-82

CD62L

APC-Cy7

®

Anti-Mouse CD62L APC-eFluor 780
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Table 2: Tissue processor Program A.

Stage

Reagent

Time (h)

1

70% EtOH

1

2

80% EtOH

1

3

80% EtOH

1

4

95% EtOH

1

5

95% EtOH

1

6

100% EtOH

1

7

100% EtOH

2

8

Xylene

1

9

Xylene

1

10

Xylene

1

11

Paraffin

1

12

Paraffin

2.5
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Table 3: H&E staining procedure.

Step

Reagent

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Clear-Rite (Thermo Scientific)
Clear-Rite (Thermo Scientific)
Clear-Rite (Thermo Scientific)
100% EtOH
100% EtOH
95% EtOH
Distilled Water
Hematoxylin 7211 (Thermo Scientific)
Distilled Water
Clarifier (Thermo Scientific)
Distilled Water
Bluing Reagent (Thermo Scientific)
Distilled Water
95% EtOH
Eosin-Y (Thermo Scientific)
100% EtOH
100% EtOH
Clear-Rite (Thermo Scientific)
Clear-Rite (Thermo Scientific)
Clear-Rite (Thermo Scientific)

26

Time

(min:sec)

3:00
3:00
3:00
1:00
1:00
1:00
1:00
1:30
1:00
0:50
1:00
1:00
1:00
0:30
1:30
1:00
1:00
1:00
1:00
1:00

Table 4: Primers used for site-directed mutagenesis.
Tag

Primer
Upstream

Sequence
Fwd. CCCTTAAAAAGCTGCTCAGCATGGACTACAAGGACGACGACGACAAGGGTGGCGGAGGTGGCTTTGGCCTGAAGCAGAGACC
Rev. GGTCTCTGCTTCAGGCCAAAGCCACCTCCGCCACCCTTGTCGTCGTCGTCCTTGTAGTCCATGCTGAGCAGCTTTTTAAGGG

FLAG
Downstream

Fwd. TGGAGGGTTGCGGGTGTCGCGGTGGCGGAGGTGGCGACTACAAGGACGACGACGACAAGTAGCACAGCAAGATCTAGGATCC
Rev. GGATCCTAGATCTTGCTGTGCTACTTGTCGTCGTCGTCCTTGTAGTCGCCACCTCCGCCACCGCGACACCCGCAACCCTCCA

Upstream

Fwd. CCCTTAAAAAGCTGCTCAGCATGGAGCAGAAGCTGATCAGCGAGGAGGACCTGGGTGGCGGAGGTGGCTTTGGCCTGAAGCAGAGACC
Rev. GGTCTCTGCTTCAGGCCAAAGCCACCTCCGCCACCCAGGTCCTCCTCGCTGATCAGCTTCTGCTCCATGCTGAGCAGCTTTTTAAGGG

Myc
Downstream

Fwd. TGGAGGGTTGCGGGTGTCGCGGTGGCGGAGGTGGCGAGCAGAAGCTGATCAGCGAGGAGGACCTGTAGCACAGCAAGATCTAGGATCC
Rev. GGATCCTAGATCTTGCTGTGCTACAGGTCCTCCTCGCTGATCAGCTTCTGCTCGCCACCTCCGCCACCGCGACACCCGCAACCCTCCA

Upstream

Fwd. CCCTTAAAAAGCTGCTCAGCATGTACCCTTACGACGTGCCTGACTACGCCGGTGGCGGAGGTGGCTTTGGCCTGAAGCAGAGACC
Rev. GGTCTCTGCTTCAGGCCAAAGCCACCTCCGCCACCGGCGTAGTCAGGCACGTCGTAAGGGTACATGCTGAGCAGCTTTTTAAGGG

HA
Downstream

Fwd. TGGAGGGTTGCGGGTGTCGCGGTGGCGGAGGTGGCTACCCTTACGACGTGCCTGACTACGCCTAGCACAGCAAGATCTAGGATCC
Rev. GGATCCTAGATCTTGCTGTGCTAGGCGTAGTCAGGCACGTCGTAAGGGTAGCCACCTCCGCCACCGCGACACCCGCAACCCTCCA

Start Codon

Tag Sequence

Glycine Linker
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Stop Codon

Table 5: Tissue weights.
Liver
Day 0

Day 3

Day 8

Day 35

Day 38

Mutant Avg. Weight (g)

1.32

1.41

1.11

1.32

1.32

WT Avg. Weight (g)

1.33

1.47

1.41

1.42

1.46

Difference (Mutant-WT)

-0.01

-0.05

-0.30

-0.10

-0.15

Percent Change (Mutant/WT)

-0.5%

-3.7%

-21.2%

-6.9%

-10.0%

P value

0.946

0.522

0.001

0.634

0.328

Mutant Standard Deviation

0.205

0.179

0.033

0.214

0.151

WT Standard Deviation

0.265

0.229

0.070

0.062

0.301

Mutant Sample Size

12

12

3

2

5

WT Sample Size

12

12

4

3

6

Day 0

Day 3

Day 8

Day 35

Day 38

Mutant Avg. Weight (g)

0.08

0.14

0.15

0.17

0.16

WT Avg. Weight (g)

0.11

0.17

0.18

0.10

0.25

Difference (Mutant-WT)

-0.03

-0.04

-0.03

0.06

-0.09

-23.8%

-21.8%

-15.0%

63.2%

-35.4%

P value

0.003

0.018

0.659

0.582

< 0.001

Mutant Standard Deviation

0.018

0.027

0.060

0.119

0.029

WT Standard Deviation

0.029

0.043

0.093

0.017

0.063

Mutant Sample Size

20

12

3

2

11

WT Sample Size

20

12

4

3

12

Day 0

Day 3

Day 8

Day 35

Day 38

Mutant Avg. Weight (g)

0.43

0.49

0.40

0.28

0.35

WT Avg. Weight (g)

0.38

0.47

0.40

0.31

0.38

Difference (Mutant-WT)

0.05

0.02

0.00

-0.03

-0.03

Percent Change (Mutant/WT)

13.3%

4.9%

0.6%

-10.9%

-7.5%

P value

0.061

0.540

0.971

0.646

0.456

Mutant Standard Deviation

0.069

0.105

0.092

0.077

0.053

WT Standard Deviation

0.057

0.075

0.052

0.032

0.068

Mutant Sample Size

12

12

3

2

5

WT Sample Size

12

12

4

3

6

Spleen

Percent Change (Mutant/WT)

Kidney
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Figure 1: Experimental setup diagram for primary and secondary infections.
For primary infection, mice were infected via tail vein injection with a dose of either 3×105 CFU/g or 1×104 CFU/g
and samples were tested either 3 or 8 days, respectively, after infection (indicated by agar plate). For secondary
infections, mice received a priming dose of 1×104 CFU/g, were allowed to recover for 35 days, and then received a
secondary infection of 3×105 CFU/g via tail vein injection. Samples were tested 3 days after secondary infection.
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Figure 2: Uninfected spleen size comparison.
Representative samples of uninfected mutant and wild type spleens from 6 month old mice are shown. Ruler mark is
equal to 1 inch. nBMP2NLStm mutant spleen size is reduced compared to wild type.
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Figure 3: Histology of wild type and mutant spleens.
Paraffin embedded spleen sections from uninfected, 6 month old mice were stained with hematoxylin and eosin
(H&E). Both wild type and mutant spleens show similar gross anatomy and white pulp to red pulp ratios.
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Figure 4: Blood cell counts of uninfected mice.
Red blood cell and white blood cell counts for uninfected mice show no difference between wild type and mutants.
Error bars indicate standard error. RBC: nwt=11 nmut=13. WBC: nwt=8 nmut=10.
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Figure 5: Lymphocyte populations in uninfected spleens.
Spleen cell types were measured using flow cytometry. No significant differences were observed between mutant
and wild type for any of the cell types tested. Error bars indicate standard error. nwt=3 nmut=3. Values shown are
percent of parent group. For example, CD4+ value is the percent of lymphocytes that are CD4+. CD4+/CD5+ value
is the percent of CD4+ lymphocytes that are also CD5+.
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Figure 6: Bacterial load on day 3 after primary infection.
Tissue samples tested 3 days after primary infection show no difference in bacterial load between wild type and
mutant mice. Results shown are CFU/mL for blood samples and CFU/g for liver, spleen, kidney and lymph node
samples. Error bars indicate standard error. nwt=12 nmut=12.
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Figure 7: Primary infection weight loss.
Wild type and mutant mice showed no difference in percent weight loss following primary infection. Error bars
indicate standard error. nwt=12 nmut=12.
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Figure 8: Tissue weights 3 days after primary infection.
Tissue weights were measured on day 3 after primary infection. Mutant and wild type mice showed no significant
difference in liver or kidney weight. Mutant spleens were 22% smaller than wild type (p=0.018). Error bars indicate
standard error. nwt=12 nmut=12.
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Figure 9: Percent weight loss 8 days after primary infection.
Wild type and mutant mice showed no difference in percent weight loss 8 days after primary infection. Results
shown include data from first 8 days after infection for mice examined on day 8 after primary infection, day 35 after
primary infection and mice from secondary infection group. Error bars indicate standard error. nwt=19 nmut=19.
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Figure 10: Bacterial load on day 8 after primary infection.
Tissue samples tested 8 days after primary infection show no significant difference in bacterial load between wild
type and mutant mice for any tissues tested. In both genotypes, bacteria was completely cleared from blood and
reduced in liver and spleen, compared to 3 days after primary infection. Results shown are CFU/mL for blood
samples and CFU/g for liver, spleen, kidney and lymph node samples. Error bars indicate standard error. nwt=4.
nmut=3.
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Figure 11: Day 35 blood cell counts.
Mice were allowed to recover for 35 days after primary infection. Red blood cell and white blood cell counts show
no difference between wild type and mutants. Error bars indicate standard error. nwt=3. nmut=2.
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Figure 12: Percent survival 8 days after primary infection.
Mice were infected with 1×104 CFU/g and percent survival was measured. Mutant mice showed slightly lower
survival to day 8 after primary infection, compared to wild type mice. Results shown include data from first 8 days
after infection for mice examined on day 8 after primary infection, day 35 after primary infection and mice from
secondary infection group. nwt=19 nmut=19.
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Figure 13: Percent survival after primary and secondary infections.
Survival rates following primary and secondary infections were measured. For primary infections, mice received a
dose of 3×105 CFU/g. For secondary infections, mice received a priming dose of 1×104 CFU/g, followed by a
secondary infection of 3×105 CFU/g 35 days later. (a.) Mutant and wild type mice showed similar survival rates
following primary infection. nwt=12 nmut=12. (b.) Mutant mice had a lower rate of survival to day 3 after secondary
infection compared to wild type. nwt=12 nmut=11. Wild type mice have an increased rate of survival after secondary
infection, compared to primary infection, indicating that they were properly immunized by the priming dose. Mutant
mice, however, actually have a lower rate of survival after secondary infection than after primary infection,
indicating that they were not properly immunized and the secondary immune response is impaired in mutant mice.
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Figure 14: Percent weight loss after secondary infection.
Wild type and mutant mice showed no difference in percent weight loss following secondary infection. Results
shown include data from mice used for secondary infection bacterial load tests as well as flow cytometry analysis.
Error bars indicate standard error. nwt=12 nmut=11
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Figure 15: Tissue weight after secondary infection.
Tissue weights were measured on day 3 after secondary infection. Mutant and wild type mice showed no significant
difference in liver or kidney weight. Mutant spleens were 35% smaller than wild type (p<0.001). Error bars indicate
standard error. For liver and kidney, nwt=6 nmut=5. For spleen, nwt=12 nmut=11.
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Figure 16: Spleen weight change at different stages of infection.
Mutant spleen weight is significantly smaller than wild type prior to infection, at day 3 after primary infection as
well as at day 3 after secondary infection. Wild type spleens increase in size over the course of primary infection and
return to baseline size by day 35. After secondary infection, wild type spleens quickly increase to their largest size.
Mutant spleen weight is larger at day 3 after primary infection than prior to infection, however it remains unchanged
after secondary infection compared to primary infection. Error bars indicate standard error. Refer to Table 5 for
sample size for each group.
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Figure 17: Bacterial load on day 3 after secondary infection.
Tissue samples tested 3 days after secondary infection show no difference in bacterial load between wild type and
mutant mice in liver, spleen, kidney or lymph node. Mutant blood samples had significantly higher bacterial load
than wild type (p=0.045). Results shown are CFU/mL for blood samples and CFU/g for liver, spleen, kidney and
lymph node samples. Error bars indicate standard error. nwt=6 nmut=6.
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Figure 18: Mutant blood has 60 fold increase in bacterial load after secondary infection.
Average mutant bacterial load was divided by the average wild type bacterial load for each tissue, resulting in the
fold change in bacterial load between wild type and mutant mice. Blood samples show a 60 fold increase in bacterial
load of mutant blood compared to wild type (p=0.045). Changes in bacterial load in other tissues were not
statistically significant. nwt=6 nmut=6.
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Figure 19: Secondary infection white blood cell counts.
Blood samples taken 3 days after secondary infection show no significant difference in white blood cell counts
(p=0.272). (a.) Average white blood cell counts for wild type and mutant mice. Error bars indicate standard error.
nwt=4. nmut=5. (b.) Dot plot showing individual samples. While this difference is not statistically significant,
possibly due to the low sample size available, it is suggestive that there could possibly be a difference in the number
of circulating lymphocytes. Values for both wild type and mutant samples are clustered together with one outlying
sample each, thereby reducing the average difference between them.
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Figure 20: Lymphocyte populations in spleen on day 3 after secondary infection.
Spleen cell types were measured using flow cytometry on day 3 after secondary infection. No significant differences
were observed between mutant and wild type for any of the cell types tested. Values shown are percent of total cells.
Error bars indicate standard error. nwt=3 nmut=3. Values shown are percent of parent group. For example, CD4+
value is the percent of cells that are CD4+. CD4+/CD5+ value is the percent of CD4+ cells that are also CD5+.
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Figure 21: Secondary infection histology.
H&E stained paraffin sections of wild type and mutant spleens following secondary infection show lower levels of
hemosiderin laden macrophages (indicated by green arrows) in mutant spleens than in wild type. This indicates that
phagocytic function of splenic macrophages is reduced in mutant mice.
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Figure 22: Lumbar lymph node size following secondary infection.
Representative samples of lumbar lymph node pairs from mutant and wild type mice 3 days after secondary
infection. Lymph node enlargement after infection is typically due to accumulation and proliferation of
lymphocytes. The failure of mutant lymph nodes to increase in size indicates that lymphocytes in the mutant mice
have an impaired ability to respond to activation or migratory signals.
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Figure 23: Lymphocyte populations in lymph node on day 3 after secondary infection.
Lymph node samples taken 3 days after secondary infection show significantly reduced levels of both CD4+
(p=0.033) and CD8+ (p=0.040) T-cells. Mutant CD4+ levels are 70% of wild type and CD8+ levels are 61%.
CD4+/CD25+ (p=0.064) and CD4+/CD62L+ (p=0.062) T-cell subsets, as well as F4/80+ (p=0.144) macrophages also
show a possible difference between mutant and wild type. Error bars indicate standard error. nwt=5. nmut=5. Values
shown are percent of parent group. For example, CD4+ value is the percent of cells that are CD4+. CD4+/CD5+
value is the percent of CD4+ cells that are also CD5+.
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Figure 24: Lymphocyte populations in thymus on day 3 after secondary infection.
Thymus samples were taken 3 days after secondary infection and cell types were measured using flow cytometry.
No significant differences were observed between mutant and wild type for any of the cell types tested. Error bars
indicate standard error. nwt=5. nmut=5. Values shown are percent of parent group. For example, CD4+ value is the
percent of cells that are CD4+. CD4+/CD5+ value is the percent of CD4+ cells that are also CD5+.
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Figure 25: Lymph node T-cells after secondary infection.
Lymph node samples taken 3 days after secondary infection show significantly reduced levels of both CD4+
(p=0.033) and CD8+ (p=0.040) T-cells. Mutant CD4+ levels are 70% of wild type and CD8+ levels are 61%. Error
bars indicate standard error. nwt=5. nmut=5.
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Figure 26: Immunofluorescent staining of HEK293 cells.
Cultured HEK293 cells show endogenous expression of nuclear BMP2. TO-PRO-3 was used to stain nuclei. BMP2
was stained using an Alexa Fluor® 488 conjugated antibody. Nuclear BMP2 is indicated by yellow areas in the
merged image.
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Figure 27: Western blot of Co-IP.
HEK293 cells were transfected with C-Myc-nBmp2. (a.) Cell lysate from transfected cells shows expression of
nBMP2. (b.) nBMP2 remains after co-immunoprecipitation pull-down using both A/G and Myc-conjugated
sepharose beads, indicating successful co-immunoprecipitation. Additional bands present are due to non-specific
binding of secondary antibody to the beads.
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